Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0D9NA
|
||||
| Former ID |
DAP000468
|
||||
| Drug Name |
Almitrine
|
||||
| Synonyms |
Almitrin; Almitrina; Almitrinum; Vectarion; Almitrine bismesylate; Almitrine dimesylate; S 2620; Almitrina [INN-Spanish]; Almitrine (INN); Almitrine Bis(methanesulfonate); Almitrine [BAN:INN]; Almitrine [INN:BAN]; Almitrinum [INN-Latin]; N,N'-diallyl-6-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}-1,3,5-triazine-2,4-diamine; 2,4-Bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine; 2,4-bis[allylamino]-6-[4-[bis(p-fluorophenyl)methyl]-1-piperazinyl]-s-triazine; 6-(4-(Bis(4-fluorphenyl)methyl)-1-piperazinyl)-N,N'-di-2-propenyl-1,3,5-triazin-2,4-diamin; 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-N,4-N-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10:J40-J44, J47] | Approved | [534891] | ||
| Therapeutic Class |
Antiinflammatory Agents
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C26H29F2N7
|
||||
| Canonical SMILES |
C=CCNC1=NC(=NC(=N1)N2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C<br />=C4)F)NCC=C
|
||||
| InChI |
1S/C26H29F2N7/c1-3-13-29-24-31-25(30-14-4-2)33-26(32-24)35-17-15-34(16-18-35)23(19-5-9-21(27)10-6-19)20-7-11-22(28)12-8-20/h3-12,23H,1-2,13-18H2,(H2,29,30,31,32,33)
|
||||
| InChIKey |
OBDOVFRMEYHSQB-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 27469-53-0
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| SuperDrug ATC ID |
R07AB07
|
||||
| SuperDrug CAS ID |
cas=027469530
|
||||
| Target and Pathway | |||||
| Target(s) | Sodium/potassium-transporting ATPase alpha-1 chain | Target Info | Binder | [537663], [537686] | |
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | |||||
| Cardiac muscle contraction | |||||
| Adrenergic signaling in cardiomyocytes | |||||
| Insulin secretion | |||||
| Thyroid hormone synthesis | |||||
| Thyroid hormone signaling pathway | |||||
| Aldosterone-regulated sodium reabsorption | |||||
| Endocrine and other factor-regulated calcium reabsorption | |||||
| Proximal tubule bicarbonate reclamation | |||||
| Salivary secretion | |||||
| Gastric acid secretion | |||||
| Pancreatic secretion | |||||
| Carbohydrate digestion and absorption | |||||
| Protein digestion and absorption | |||||
| Bile secretion | |||||
| Mineral absorption | |||||
| Reactome | Ion transport by P-type ATPases | ||||
| WikiPathways | Iron uptake and transport | ||||
| References | |||||
| Ref 537663 | Flux-dependent increase in the stoichiometry of charge translocation by mitochondrial ATPase/ATP synthase induced by almitrine. Biochim Biophys Acta. 1990 Jul 17;1018(1):91-7. | ||||
| Ref 537686 | Almitrine, a new kind of energy-transduction inhibitor acting on mitochondrial ATP synthase. Biochim Biophys Acta. 1989 Aug 3;975(3):325-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.